ArticleGeneral thoracic and cardiovascular surgery2021
Development of a new risk model for a prognostic prediction after transcatheter aortic valve replacement.
Article in General thoracic and cardiovascular surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- A novel survival prediction model after isolated surgical aortic valve replacement in the transcatheter aortic valve replacement era.General thoracic and cardiovascular surgery · 2026Article
- New risk model for prognostic prediction after surgical aortic valve replacement in hemodialysis patients.General thoracic and cardiovascular surgery · 2026Article
- Transcatheter aortic valve replacement explantation experience in Japanese high-volume center.Annals of cardiothoracic surgery · 2025Article
- Artificial Intelligence in the Screening, Diagnosis, and Management of Aortic Stenosis.Reviews in cardiovascular medicine · 2024Review
- A Novel Frailty Score Based on Laboratory Parameters (FIMS Score) for the Management of Older Patients with Severe Aortic Stenosis.Journal of clinical medicine · 2023Article
- A Risk Model for 1-Year Mortality After Transcatheter Aortic Valve Replacement From the J-TVT Registry.JACC. Asia · 2022Article
- Machine learning applications in cardiac computed tomography: a composite systematic review.European heart journal open · 2022Review
- Deoxyribonuclease is prognostic in patients undergoing transcatheter aortic valve replacement.European journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines for transcatheter aortic valve replacement (TAVR) recommend that TAVR should be performed in patients with a life expectancy > 1 year. However, it is challenging to estimate the patients' life expectancy because it is related to various factors, including frailty and nutritional status. HYPOTHESIS: A new risk model can estimate the prognosis of patients after TAVR.
methodsWe randomly divided 388 patients with aortic stenosis (AS) undergoing TAVR from October 2009 to August 2016 into two groups (2:1 ratio; training cohort, 259; validation cohort, 129). Using 94 baseline factors in the training cohort, we developed possible scoring models by the Cox proportional hazard regression model with the overall survival as the endpoint. Then, cross-validated 5-year C-statistics were calculated to assess the accuracy of the model.
resultsOf 94 baseline factors, 12 factors were finally identified (5-year C-statistics in the training cohort: 0.709)-age, gender, body mass index, left ventricular ejection fraction, % vital capacity, forced expiratory volume 1.0 (s) %, albumin, hemoglobin, creatine, platelet, creatine kinase, and prothrombin time-international normalized ratio. The cross-validated 1-, 3-, and 5-year C-statistics in the validation cohort were 0.792, 0.758, and 0.778, respectively. Furthermore, calibration plots in the validation cohort revealed that 5-year survival is well predicted (r = 0.962).
conclusionsThe new survival prediction model after TAVR could provide appropriate guidance during decision making regarding the TAVR implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.